Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From Mendel to Gene Therapy.
Jeffrey SL, Brigham DA, Chawla SP, Federman N, Hall FL, Gordon EM. Jeffrey SL, et al. Among authors: chawla sp. Anticancer Res. 2023 Oct;43(10):4257-4261. doi: 10.21873/anticanres.16620. Anticancer Res. 2023. PMID: 37772566 No abstract available.
The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of C-MYC.
Aoki Y, Kubota Y, Han Q, Masaki N, Obara K, Bouvet M, Chawla SP, Tome Y, Nishida K, Hoffman RM. Aoki Y, et al. Among authors: chawla sp. Cancer Genomics Proteomics. 2023 Dec;20(6suppl):679-685. doi: 10.21873/cgp.20415. Cancer Genomics Proteomics. 2023. PMID: 38035708 Free PMC article.
A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
Kenney RT, Cini JK, Dexter S, DaFonseca M, Bingham J, Kuan I, Chawla SP, Polasek TM, Lickliter J, Ryan PJ. Kenney RT, et al. Among authors: chawla sp. Front Immunol. 2024 Feb 29;15:1362775. doi: 10.3389/fimmu.2024.1362775. eCollection 2024. Front Immunol. 2024. PMID: 38487528 Free PMC article. Clinical Trial.
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BP. Subbiah V, et al. Among authors: chawla sp. Clin Cancer Res. 2023 Aug 15;29(16):2988-3003. doi: 10.1158/1078-0432.CCR-23-0974. Clin Cancer Res. 2023. PMID: 37265425 Free PMC article. Clinical Trial.
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311).
Chawla SP, Tellez WA, Chomoyan H, Valencia C, Ahari A, Omelchenko N, Makrievski S, Brigham DA, Chua-Alcala V, Quon D, Moradkhani A, Gordon EM. Chawla SP, et al. Front Oncol. 2023 May 10;13:1116937. doi: 10.3389/fonc.2023.1116937. eCollection 2023. Front Oncol. 2023. PMID: 37234994 Free PMC article.
137 results